Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy Biomarkers of DAOIB for Dementia
NCT05582161Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Oct 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of daoib in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Chang Gung Memorial Hospital. Started Oct 2022; status: recruiting.
02
Drugs
daoib
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT05582161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582161.